Alterations of p53, Bcl-2, and hMSH2 protein expression in the cirrhotic, macroregenerative, dysplastic nodules and hepatocellular carcinomas in Upper Egypt

Liver International

Volumn 24, Issue 6, 2004, Pages 552-560

  Hussein, Mahmoud R ^a  

^a Assiut University   (Egypt)

Author keywords

Bcl 2; HCC; hMSH2; p53

Indexed keywords

PROTEIN MSH2; PROTEIN P53;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EGYPT; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; EGYPT; FEMALE; FOCAL NODULAR HYPERPLASIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROBABILITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 11144351630     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0962.x     Document Type: Article

References (58)

1. Attia M A. Prevalence of hepatitis B and C in Egypt and Africa. Antiviral Ther 1998; 3: 1-9.
2. Abdel-Wahab M, el-Enein A A, Abou-Zeid M, et al. Hepatocellular carcinoma in Mansoura-Egypt: experience of 385 patients at a single center. Hepatogastroenterology 2000; 47: 663-8.
3. Sun M, Eshleman J R, Ferrell L D, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001; 33: 1415-24.
4. Hussein M R, Hassan M, Wood G S. Morphological changes and apoptosis in radial growth phase melanoma cell lines following ultraviolet-B irradiation. Am J Dermatopathol 2003; 25: 466-72.
5. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24: 77-88.
6. Fang D C, Fang L, Wang R Q, Yang S M. Nuclear and mitochondrial DNA microsatellite instability in hepatocellular carcinoma in Chinese. World J Gastroenterol 2004; 10: 371-5.
7. Chiappini F, Gross-Goupil M, Saffroy R, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004; 25: 541-7.
8. Koo S H, Ihm C H, Kwon K C, Lee J S, Park J W, Kim J W. Microsatellite alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2003; 146: 139-44.
9. Fang L, Fang D C. Mitochondrial microsatellite instability in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 95.
10. Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
11. Wang L, Bani-Hani A, Montoya D P, et al. hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int J Oncol 2001; 19: 567-70.
12. Park Y M, Choi J Y, Bae S H, et al. Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea. Hepatol Res 2000; 17: 102-11.
13. Yano M, Asahara T, Dohi K, Mizuno T, Iwamoto K S, Seyama T. Close correlation between a p53 or hMSH2 gene mutation in the tumor and survival of hepatocellular carcinoma patients. Int J Oncol 1999; 14: 447-51.
14. Kazachkov Y, Yoffe B, Khaoustov V I, Solomon H, Klintmalm G B, Tabor E. Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. Liver 1998; 18: 156-61.
15. Huang B J, Zhu Z Y, Liang Q W, Fang Y. Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance. Zhonghua Bing Li Xue Za Zhi 2003; 32: 20-4.
16. Ding X, Park Y N, Taltavull T C, et al. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn J Infect Dis 2003; 56: 12-8.
17. Nakano A, Watanabe N, Nishizaki Y, Takashimizu S, Matsuzaki S. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma. Hepatol Res 2003; 25: 158-65.
18. Anzola M, Burgos J J. Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis. Expert Rev Mol Med 2003; 2003: 1-16.
19. Kobayashi T, Sugawara Y, Shi Y Z, Makuuchi M. Telomerase expression and p53 status in hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 3166-71.
20. Paiva C, Oshima C T, Lanzoni V P, Forones N M. Apoptosis, PCNA and p53 in hepatocellular carcinoma. Hepatogastroenterology 2002; 49: 1058-61.
21. Weihrauch M, Lehnert G, Kockerling F, Wittekind C, Tannapfel A. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 2000; 88: 1030-6.
22. Hsia C C, Nakashima Y, Thorgeirsson S S, et al. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep 2000; 7: 353-6.
23. Katiyar S, Dash B C, Thakur V, Guptan R C, Sarin S K, Das B C. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000; 88: 1565-73.
24. Garcia E J, Lawson D, Cotsonis G, Cohen C. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol 2002; 10: 210-7.
25. Guo X Z, Shao X D, Liu M P, et al. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis; in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 2002; 8: 1059-62.
26. Chang Y C, Xu Y H. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res 2000; 10: 233-42.
27. Feng D, Zheng H, Shen M, Cheng R, Yan Y. Regulation of p53 and bcl-2 proteins to apoptosis and cell proliferation in liver cirrhosis and hepatocellular carcinoma. Hunan Yi Ke Da Xue Xue Bao 1999; 24: 325-8.
28. Hamazaki K, Gochi A, Matsubara N, Mori M, Orita K. Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. Acta Med Okayama 1995; 49: 227-30.
29. Yoon D S, Cheong J H, Park Y N, Kwon S W, Chi H S, Kim B R. Cell proliferation index and the expression of p53 and Bcl-2 in tumorous and non-tumorous lesions of hepatocellular carcinoma and metastatic liver cancer. Yonsei Med J 1998; 39: 424-9.
30. Greenblatt M S, Grollman A P, Harris C C. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 1996; 56: 2130-2136.
31. Buller R E, Shahin M S, Holmes R W, Hatterman M, Kirby P A, Sood A K. p53 Mutations and microsatellite instability in ovarian cancer: yin and yang. Am J Obstet Gynecol 2001; 184: 891-902; discussion 902-893.
32. Karachristos A, Liloglou T, Field J K, Deligiorgi E, Kouskouni E, Spandidos D A. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol Cell Biol Res Commun 1999; 2: 155-61.
33. Warnick C T, Dabbas B, Ford C D, Strait K A. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J Biol Chem 2001; 276: 27363-70.
34. Hussein M R, Sun M, Roggero E, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002; 34: 35-44.
35. Chan W Y, Cheung K K, Schorge J O, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000; 156: 409-17.
36. Wikonkal N M, Berg R J, van Haselen C W, et al. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
37. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed M K, Selim O E, Badran H M. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt - a single center experience. Hepatol Res 2001; 19: 170-9.
38. Stauber R. Epidemiology and transmission of hepatitic C. Wien Med Wochenschr 2000; 150: 460-2.
39. Yates S C, Hafez M, Beld M, et al. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. Am J Trop Med Hyg 1999; 60: 714-20.
40. Shieh Y S, Nguyen C, Vocal M V, Chu H W, Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma. Int J Cancer 1993; 54: 558-62.
41. Kamal S, Madwar M. Bianchi L, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281-9.
42. Hassan M M, Zaghloul A S, El-Serag H B, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33: 123-6.
43. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
44. Khan M H, Farrell G C, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-20.
45. Hepatocellular Carcinoma: Eastern and Western Experiences Proceedings of an international congress. Tokyo, Japan, December 9, 2000. Hepatogastroenterology 2002; 49: 5-95.
46. Caruso M L, Valentini A M. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res 1999; 19: 3853-6.
47. Kang Y K, Kim C J, Kim W H, Kim H O, Kang G H, Kim Y I. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 1998; 432: 27-32.
48. Zhao M, Zimmermann A. Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity. J Clin Pathol 1997; 50: 394-400.
49. Cohen C, DeRose P B. Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. Mod Pathol 1994; 7: 536-9.
50. Zhao M, Zhang N X, Laissue J A, Zimmermann A. Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Arch 1994; 424: 613-21.
51. Charlotte F, L'Hermine A, Martin N, et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994; 144: 460-5.
52. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002; 95: 1938-45.
53. Zhao M, Zhang N X, Economou M, Blaha I, Laissue J A, Zimmermann A. Immunohistochemical detection of bcl-2 protein in liver lesions: bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology 1994; 25: 237-45.
54. Chiu C T, Yeh T S, Hsu J C, Chen M F. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 2003; 48: 670-6.
55. Watson A J, Merritt A J, Jones L S, et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73: 889-95.
56. Wani Y, Notohara K, Tsukayama C, Okada S. Reduced expression of hMLH1 and hMSH2 gene products in high-grade hepatocellular carcinoma. Acta Med Okayama 2001; 55: 65-71.
57. Yamamoto H, Itoh F, Fukushima H, et al. Infrequent widespread microsatellite instability in hepatocellular carcinomas. Int J Oncol 2000; 16: 543-7.
58. Macdonald G A, Greenson J K, Saito K, Cherian S P, Appelman H D, Boland C R. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998; 28: 90-7.